Genomics Bioscience & Technology Co Debt/EBITDA
The Total Debt to EBITDA Ratio of Genomics Bioscience & Technology Co (4195.TWO) as of Oct 15, 2026 is -4.04. In the previous year, Total Debt to EBITDA Ratio was -2.36 — a change of 71.42% (lower).
Get this data via API
Financial Data API
Debt/EBITDA
-4.04
YoY
71.42%
Last updated:
The Genomics Bioscience & Technology Co Debt/EBITDA history
3 Years
10 Years
25 Years
Max
| YEAR | Debt/EBITDA | YoY |
|---|---|---|
| -4.04 | +71.42% | |
| -2.36 | +37.79% | |
| -1.71 | -157.13% | |
| 2.99 | -52.78% | |
| 6.34 | -88.24% | |
| 53.91 | +1,227.53% | |
| 4.06 | -355.98% | |
| -1.59 | -36.70% | |
| -2.51 | +71.82% | |
| -1.46 | -30.14% | |
| -2.09 | +21.80% | |
| -1.71 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Genomics Bioscience & Technology Co Stock analysis
Frequently Asked Questions about Genomics Bioscience & Technology Co stock
Total Debt to EBITDA Ratio of Genomics Bioscience & Technology Co is -4.04 in 2025.
Total Debt to EBITDA Ratio of Genomics Bioscience & Technology Co changed from -2.36 to -4.04, representing a 71.42% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Genomics Bioscience & Technology Co since 2006 – with annual values, charts, and detailed analysis.
Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Genomics Bioscience & Technology Co with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Leverage — Genomics Bioscience & Technology Co
All Key Metrics — Genomics Bioscience & Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth